Two fillers list the same active ingredient and behave nothing alike in the clinic. One holds for a year and the other settles in four months, and the difference sits in a crosslinking step that the label never describes.

This note is for buyers and clinicians involved in sourcing dermal fillers. It covers what crosslink density changes, how degradation actually happens, and which batch records decide whether a recall can be handled quickly.

Crosslink density sets how long a filler lasts, and the batch records behind it decide how fast a recall can be traced

Hyaluronic acid is the same molecule across most of the category. What differs is how much of it has been crosslinked and with what.

Higher crosslink density produces a firmer gel that resists enzymatic breakdown for longer, and also produces more residual crosslinker that has to be removed.

The clinical consequence is that products cannot be substituted on the basis of concentration alone, even when the stated percentage matches.

Gel fraction and swelling ratio are the numbers that predict behaviour

Gel fraction describes how much of the material actually became part of the network. The remainder is soluble and leaves early.

Swelling ratio describes how much water the network takes up, and it drives both the initial volume and the way the product feels under the skin.

Two products can match on HA concentration and differ on both numbers, which is why a specification that stops at concentration is not a specification.

Particulate and monolithic gels behave differently in tissue

A particulate product is made of crosslinked particles suspended in a carrier. The body clears the carrier first and the particles later.

A monolithic gel is one continuous network, and its breakdown is more uniform but also more dependent on the injection plane.

Neither is better in the abstract. The choice has to match the tissue plane, the volume being placed and how long the result needs to hold.

Residual crosslinker is the impurity that purification exists to remove

The crosslinking reaction leaves unreacted BDDE behind, and the washing steps after it are what bring the residual down to an acceptable level.

Washing is time and water. A supplier under pressure to increase yield has an obvious place to economise, and the finished product looks identical.

Residual testing belongs in the certificate of analysis for every batch, with the limit stated numerically rather than referenced to an internal standard.

Degradation is enzymatic and mechanical at the same time

Hyaluronidase breaks the polymer chains, and the rate depends on the tissue and on the individual. That part is outside the supplier's control.

Mechanical loading from facial movement also breaks the network down, and a product placed in a high-mobility area will not last as long as the same product in a static plane.

Claims about duration are therefore averages taken from a population. A buyer should read them as a range and not as a promise for a particular patient.

Rheology has to match the injection plane

A gel that is too soft spreads beyond the intended plane, and one that is too firm produces palpable nodules.

Elastic modulus and extrusion force describe this behaviour more usefully than the stated HA concentration, and both can be measured before purchase.

Asking for the rheology profile is a normal request. A supplier who cannot produce one is selling on label rather than on data.

Sterility and endotoxin are separate failures with separate tests

Sterility confirms that no viable organism is present. Endotoxin testing confirms that no pyrogenic fragment is present, and the two do not substitute for each other.

Terminal sterilisation can degrade the gel, so many products are manufactured aseptically instead, which puts the burden on the filling environment.

Both results belong on the batch record. A certificate that lists sterility and omits endotoxin is incomplete for an injectable.

Batch traceability decides how a recall is handled

When a problem appears in one lot, the difference between a contained event and a market-wide one is whether the units can be traced to the patient.

That requires the lot number to survive from the syringe through the clinic record, and it requires the distributor to know which clinics received which lot.

The dermal filler market has grown faster than the traceability systems behind it, and the gap is where recalls become expensive.

Regulatory pathways differ, and the label follows the strictest market

A product cleared in one jurisdiction may be sold elsewhere under a different classification, with different clinical evidence behind the claim.

Buyers importing through distribution channels should check which approval the units actually carry, rather than which approval the brand holds somewhere.

Where a supplier is entering a new market, the opportunity analysis framing is useful for understanding why the same product appears under several names.

What a buyer should require in the specification

State the crosslinker, the degree of crosslinking, the gel fraction, the swelling ratio and the residual limit. Those five numbers describe the product; concentration alone does not.

Add the rheology profile and the extrusion force for the intended needle gauge, because those decide how the product behaves in the clinic.

Require the full batch record with each shipment, and audit the filling environment at least once. The rest of the specification is only as good as the process behind it.

Packaging and needle compatibility decide the last metre of the process

A gel that behaves correctly in the laboratory can extrude badly through the needle supplied with it, and the clinic experiences that as a product problem.

Syringe barrel friction, plunger breakaway force and needle inner diameter all contribute, and none of them appear on a label aimed at clinicians.

Testing extrusion force with the actual needle gauge and at the actual temperature is the only way to know. A cold syringe behaves differently from one at room temperature.

Lidocaine-containing variants add a second active and a second stability question

Adding a local anaesthetic changes the pH and the ionic environment, which can affect both the gel and the stability of the mixture over shelf life.

The clinical benefit is real, and the formulation work behind it is not trivial. A supplier who offers the variant without stability data is offering a claim.

Ask for the stability protocol and the conditions used. If the answer is a shelf life without a protocol, the number is a hope.

Counterfeit and diverted product reaches clinics through ordinary channels

Because the product is expensive per unit and small enough to ship easily, diverted and copied units appear in markets with weak oversight.

Serial numbers, tamper evidence and a verified distributor list are the practical defences. Checking them is a five-minute task that is often skipped under time pressure.

Buyers who source outside the authorised chain should assume the burden of proof sits with them, and document what was checked.

FAQ: questions buyers ask

If two fillers contain the same percentage of HA, are they equivalent?

No. The percentage describes how much hyaluronic acid is present, not how much of it has been crosslinked, how much remains soluble, or how firm the resulting gel is. Those differences decide duration and behaviour in tissue.

Why does the same product last longer in some patients?

Enzymatic breakdown varies between individuals, and mechanical loading varies with the treatment area and with facial movement. Published duration figures are population averages, not guarantees.

Is aseptic filling less safe than terminal sterilisation?

It is a different control strategy rather than a lower standard. Aseptic filling places the burden on the environment and on process validation, while terminal sterilisation can degrade a gel enough to change its behaviour.

What is the single most useful test on a certificate of analysis?

There is no single test, but residual crosslinker is the one most often missing and most closely tied to purification discipline. A numeric limit beats a statement of compliance.

How quickly should a recall be executable?

Fast enough to reach the clinics holding the affected units before further treatments are given. That is a distribution record question, and it should be tested before it is needed.